The report “Digital Pathology Market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.8 billion by 2028, growing at a CAGR of 13.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth in the digital pathology industry is mainly driven by factors such as the growing awareness of early cancer diagnosis in emerging economies, growing applications of digital pathology in drug development and companion diagnostics, and the increasing adoption of digital pathology to enhance lab efficiency.

The digital pathology industry is poised for remarkable growth and transformation in the near future. With advancements in technology and the increasing demand for efficient and accurate diagnostic solutions, digital pathology is set to revolutionize healthcare systems worldwide. The integration of artificial intelligence and machine learning algorithms with digital pathology platforms will enable pathologists to analyze and interpret large volumes of digital slides more efficiently, leading to faster and more accurate diagnoses. Moreover, the widespread adoption of telepathology will facilitate remote consultations and second opinions, bridging the gap between experts and underserved areas. This digital revolution in pathology will not only enhance patient care by enabling faster diagnosis and personalized treatment plans but also streamline pathology workflows, reduce costs, and facilitate data-driven research for improved clinical outcomes.

Download Report Brochure @ https://bit.ly/3XdyXDx

Top Key Player

The major players in the global Digital Pathology market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), and Hamamatsu Photonics (Japan)were the top players in the Digital Pathology market during the forecast period. Other major players in the market include Sectra AB (Sweden), F. Hoffmann-La Roche Ltd. (Switzerland), Visiopharm A/S (Denmark), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN (US), Huron Digital Pathology (Canada), Corista (US), Indica Labs (US), OptraSCAN (India), Glencoe Software (US), Inspirata (US), Mikroscan Technologies (US), and Kanteron Systems (Spain).

Digital Pathology Market Dynamics:

Drivers:

1. Increasing adoption of digital pathology to enhance lab efficiency
2. Rising incidence of cancer
3. Growing applications of digital pathology in drug development and companion diagnostics
4. Growing awareness of early cancer diagnosis in emerging economies
5. Recommendations for cancer screening

Restraints:

1. High cost of digital pathology systems

Opportunities:

1. Introduction of affordable scanners for private pathology practices
2. Growing demand for personalized medicine
3. High growth opportunities in emerging economies

Challenges:

1. Shortage of trained pathologists

The human pathology segment has accounted for the largest market share during the forecast period.

Based on type, the digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of 66.5% of digital pathology type market in 2022. The growing awareness of early cancer diagnosis in emerging economies, and increasing collaborations among academic research institutes, universities, and pathology laboratories drives the growth of the human pathology segment in the digital pathology market.

The scanners segment accounted for the largest share of 44.9% of the global digital pathology market

Basesd on product, the global digital pathology market is segmented into scanners, software, and storage systems. The scanners segment accounted for the largest share of 44.9% of the global digital pathology market in 2022. The large share of this segment can be attributed to the restrictions implemented in many countries owing to the COVID-19 outbreak are also expected to increase the installation of scanners to promote the remote viewing of tests by pathologists.

Drug discovery was the largest application segment of the digital pathology market.

Based on application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. In 2022, drug discovery was the largest application segment of the digital pathology market. The growth in the rising number of preclinical & clinical studies, high throughput screening and imaging, and increasing use of toxicology testing for illicit drugs are the major factors responsible for the large share of the drug discovery application segment.

North America accounted for the largest share of the Digital Pathology market

In 2022, North America accounted for the largest share and highest growth rate of the digital pathology market in 2022. The highest growth rate of the market can be attributed to the rising prevalence of cancer, growing geriatric population, and the presence of well-developed healthcare infrastructure in the region are expected to drive the growth of the market in North America.

Request 10% Customization: https://bit.ly/3CAVyAk

Recent Developments:

• In 2022, Danaher Corporation partnered with Indica Labs to deliver compatible digital pathology workflow solutions by maintaining file compatibility between Leica Biosystems Aperio GT 450 family of scanners with Indica Labs Halo family of software solutions.
• In 2022, Hamamatsu received US FDA 510(k) clearance for the NanoZoomer S360MD Slide scanner system for primary diagnostic use.
• In 2022, F. Hoffmann-LA roche ltd. Launched the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics.
• In 2021, Koninklijke Philips launched the next-generation digital pathology solution, which features a comprehensive and scalable suite of software tools and capabilities in digital pathology.

Related Link: Digital Pathology Market

Table of Content:

• DANAHER CORPORATION
  • MnM view
    • Right to win

Danaher holds a prominent position in the Digital pathology market due to its extensive geographical reach and impressive range of products. Danaher employs a strategic approach that emphasizes product introductions and collaborative efforts to enhance its market share. The company strengthens its position in the market by expanding its technology offerings through partnerships to solidify its presence in the Digital pathology market. Furthermore, Its subsidiary, Leica Biosystems, offers a portfolio from biopsy to diagnosis across radiology, pathology, surgery, and oncology.

• KONINKLIJKE PHILIPS N.V.
  • MnM view
    • Right to win

Koninklijke Philips N.V. holds a prominent position in the Digital pathology market, boasting a widespread presence across North America, the Asia Pacific, Europe and Africa. Philips is a key player in diagnostic imaging systems, patient monitoring and health informatics, image-guided therapy, consumer health, and home care. The company operates through four major segments: Diagnosis & Treatment, Connected Care, Personal Health, and Others. The Diagnosis & Treatment segment is further divided into Diagnostic Imaging, Image-guided Therapy, Ultrasound, and Enterprise Diagnostic Informatics. The company offers digital pathology products through the Diagnostic Imaging segment.

• HAMAMATSU PHOTONICS K.K.
  • MnM view
    • Right to win

Hamamatsu Photonics K.K. is a leading provider of photoelectron conversion technologies. The company is organized into three main businesses—Electron Tube, Opto-semiconductor, and Imaging and Measurement Instruments. The Imaging and Measurement Instruments segment offers a wide range of scanners and software for digital pathology solutions. Hamamatsu geographically operates across the Americas, Europe, and Asia. The company has 17 subsidiaries operating across the US, Japan, China, Germany, France, Sweden, Italy, and the UK. Some of its major subsidiaries are Takaoka Electronics (Japan), Hamamatsu Electronic Press (Japan), Photonics Management (US), Hamamatsu Photonics Europe (Germany), Hamamatsu Photonics Scientific Instrument (China), and Hangzhou Hamamatsu Photonics Science and Technology (China).

• HOFFMANN-LA ROCHE LTD.
  • MnM view
    • Right to win

Roche is a leader in personalized healthcare, providing products under two major operating segments, namely, Pharmaceuticals and Diagnostics. The Diagnostics segment provides a wide range of products. The Pathology Lab segment offers digital pathology scanners and software solutions in the market. The company is engaged in the innovation and manufacture of instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. Roche offers comprehensive digital software and solutions in more than 100 countries across the globe. Some of its notable subsidiaries are Roche Diagnostics Corporation (US), Roche Diagnostics K.K. (Japan), Roche Diagnostics S.L. (Spain), Signature Diagnostics GmbH (Germany), and Roche Diagnostics Australia Pty Limited (Australia).

• SECTRA AB
  • MnM view
    • Right to win

Sectra AB is a leading provider of imaging IT solutions. The company conducts research, development, and sales of high-tech products and services in the niche markets of medical imaging, IT, and cybersecurity. The company primarily operates in three segments: Imaging IT Solutions, Business Innovation, and Secure Communications. The company’s Imaging IT Solutions segment works towards achieving patient-centric care. Under this segment, Sectra offers an enterprise imaging solution, which comprises PACS for intense imaging departments (such as radiology, pathology, cardiology, and orthopedics) and VNA that help share and merge images.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.